Advertisement


Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Advertisement